DIVALPROEX SODIUM VS PLACEBO IN CHILD/ADOLESCENT AUTISM

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这项拟议的研究旨在评估双丙戊酸钠（DS）与安慰剂治疗儿童/青少年自闭症的疗效，以满足DSM-IV和自闭症诊断访谈（ADI）标准。目前，尽管行为和教育疗法以及各种药物可能在某些自闭症症状的管理中发挥作用，但还没有fda批准的治疗这种疾病的方法。我们的研究将是一项为期12周的安慰剂对照双丙戊酸钠与安慰剂的双盲试验，在40名5-17岁的自闭症谱系障碍儿童和青少年中进行，这些儿童和青少年符合DSM-IV、ADI和ADOS的自闭症标准。这些患者将从西奈山的门诊儿科和青少年诊所以及通过广告和当地媒体招募。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The proposed study is designed to assess the efficacy of treatment with divalproex sodium (DS) vs. placebo in childhood/adolescent autism fulfilling DSM-IV and Autism Diagnostic Interview (ADI) criteria. Currently, there are no FDA-approved treatments for this disorder, although behavioral and educational therapies and a variety of medications may play a role in the management of some autistic symptoms. Our study will be a 12-week placebo-controlled, double-blind trial of Divalproex sodium versus placebo in 40 autistic spectrum disorder children and adolescents ages 5-17 years who meet DSM-IV, ADI, and ADOS criteria for autistic disorder. The patients will be recruited from the outpatient pediatrics and adolescent clinics at Mt. Sinai as well as through advertisements and local media.